Tolvaptan
Jalal K Ghali1, Bashar Hamad, Uma Yasothan
1Harper University Hospital, 3990 John R Street, 9 Webber Core, Detroit, MI 48201, USA. JGhali@dmc.org
Abstract:
In May 2009, tolvaptan (Samsca; Otsuka), a selective vasopressin V(2) receptor antagonist, was approved by the US FDA for the treatment of clinically significant hypervolaemic and euvolaemic hyponatraemia.
More Related Videos
06:08Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump
Published on: March 11, 2017
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
Related Concept Videos
Antihypertensive Drugs: Potassium-Sparing Diuretics
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Renal Drug Excretion: Tubular Secretion
Renal Drug Excretion: Tubular Reabsorption
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
